[JCY] QoQ Annualized Quarter Result on 30-Jun-2013 [#3]

Stock
[JCY] JCY INTERNATIONAL BERHAD
Announcement Date
19-Aug-2013
Admission Sponsor
-
Sponsor
-
Financial Year
30-Sep-2013
Quarter
30-Jun-2013 [#3]
Profit Trend
QoQ- 14.95%
YoY- -113.77%
Quarter Report
Latest QR
Upcoming QR
JCY's Result
JCY's Financial Summary
View:
Show?
Annualized Quarter Result
31/03/14 31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 CAGR
Revenue 1,904,268 1,907,252 1,594,292 1,573,250 1,556,496 1,507,296 2,241,289 -10.30%
PBT 139,124 123,424 -55,249 -76,865 -90,436 -100,372 428,756 -52.81%
Tax -2,414 -2,412 -6,362 -2,248 -2,580 -2,544 -1,460 39.86%
NP 136,710 121,012 -61,611 -79,113 -93,016 -102,916 427,296 -53.25%
-
NP to SH 136,710 121,012 -61,611 -79,113 -93,016 -102,916 427,296 -53.25%
-
Tax Rate 1.74% 1.95% - - - - 0.34% -
Total Cost 1,767,558 1,786,240 1,655,903 1,652,363 1,649,512 1,610,212 1,813,993 -1.71%
-
Net Worth 1,119,237 1,107,990 1,071,707 1,064,778 1,069,887 1,082,846 1,136,675 -1.02%
Dividend
31/03/14 31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 CAGR
Div 40,566 - 20,266 27,093 40,618 81,036 163,491 -60.54%
Div Payout % 29.67% - 0.00% 0.00% 0.00% 0.00% 38.26% -
Equity
31/03/14 31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 CAGR
Net Worth 1,119,237 1,107,990 1,071,707 1,064,778 1,069,887 1,082,846 1,136,675 -1.02%
NOSH 2,028,338 2,030,402 2,026,677 2,032,020 2,030,917 2,025,905 2,043,645 -0.50%
Ratio Analysis
31/03/14 31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 CAGR
NP Margin 7.18% 6.34% -3.86% -5.03% -5.98% -6.83% 19.06% -
ROE 12.21% 10.92% -5.75% -7.43% -8.69% -9.50% 37.59% -
Per Share
31/03/14 31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 CAGR
RPS 93.88 93.93 78.67 77.42 76.64 74.40 109.67 -9.85%
EPS 6.74 5.96 -3.04 -3.89 -4.58 -5.08 20.91 -53.02%
DPS 2.00 0.00 1.00 1.33 2.00 4.00 8.00 -60.34%
NAPS 0.5518 0.5457 0.5288 0.524 0.5268 0.5345 0.5562 -0.52%
Adjusted Per Share Value based on latest NOSH - 2,036,031
31/03/14 31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 CAGR
RPS 88.80 88.94 74.34 73.36 72.58 70.29 104.51 -10.29%
EPS 6.37 5.64 -2.87 -3.69 -4.34 -4.80 19.93 -53.28%
DPS 1.89 0.00 0.95 1.26 1.89 3.78 7.62 -60.55%
NAPS 0.5219 0.5167 0.4997 0.4965 0.4989 0.5049 0.53 -1.02%
Price Multiplier on Financial Quarter End Date
31/03/14 31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 CAGR
Date 31/03/14 31/12/13 30/09/13 28/06/13 29/03/13 31/12/12 28/09/12 -
Price 0.725 0.635 0.63 0.67 0.525 0.62 0.78 -
P/RPS 0.77 0.68 0.80 0.87 0.69 0.83 0.71 5.56%
P/EPS 10.76 10.65 -20.72 -17.21 -11.46 -12.20 3.73 102.77%
EY 9.30 9.39 -4.83 -5.81 -8.72 -8.19 26.81 -50.66%
DY 2.76 0.00 1.59 1.99 3.81 6.45 10.26 -58.36%
P/NAPS 1.31 1.16 1.19 1.28 1.00 1.16 1.40 -4.33%
Price Multiplier on Announcement Date
31/03/14 31/12/13 30/09/13 30/06/13 31/03/13 31/12/12 30/09/12 CAGR
Date 19/05/14 20/02/14 21/11/13 19/08/13 22/05/13 21/02/13 21/11/12 -
Price 0.745 0.745 0.585 0.675 0.65 0.59 0.85 -
P/RPS 0.79 0.79 0.74 0.87 0.85 0.79 0.78 0.85%
P/EPS 11.05 12.50 -19.24 -17.34 -14.19 -11.61 4.07 94.73%
EY 9.05 8.00 -5.20 -5.77 -7.05 -8.61 24.60 -48.68%
DY 2.68 0.00 1.71 1.98 3.08 6.78 9.41 -56.74%
P/NAPS 1.35 1.37 1.11 1.29 1.23 1.10 1.53 -8.01%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment